Deferoxamine (mesylate) [138-14-7]
Référence HY-B0988-1ml
Conditionnement : 10mM/1mL
Marque : MedChemExpress
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Deferoxamine mesylate Chemical Structure
CAS No. : 138-14-7
* Veuillez sélectionner la quantité avant d'ajouter des articles.
This product is a controlled substance and not for sale in your territory.
- PAI1 mRNA expression in iHUVEC treated with increasing doses of either CoCl2, Deferoxamine (DFO), 1, 4-DPCA or DMOG.
- Deferoxamine (DFOM; 100 μM; 24 h) attenuated the abnormal increase of ROS and LPO in macrophages elicited by CdTe QDs.
- The specific inhibitor of ferroptosis Fer-1 (100 μM) and Lip-1 (5 μM), and the iron chelator Deferoxamine (DFOM;100 μM) restored the cellular activity of RAW264.7 macrophages after treatment for 24 h.
- The expression of ferroptosis-related proteins in lung cancer cells is detected after Curcumenol treatment with or without Deferoxamine (DFO; 20 μM) by western blotting.
- H1299 cells are treated with Curcumenol with or without Deferoxamine (DFO; 20 μM) for 24 h, and the cell viability is analyzed.
- Deferoxamine (DFO; 0.5 μM; for 48 h) could rescue iron overload‐induced cell death in both iHep‐Orgs and iHep.
- Deferoxamine (DFO; 10 μM; 72 h) can markedly reverse the cell growth prevented by a2 in MGC-803 and MKN-45 cells.
- Propidium iodide staining confirmed that DFO inhibited metformin-induced cell death in T47D cells Deferoxamine (20 μM; 48 h).
- Representative results of wound healing after the treatment with the combination of ferroptosis inhibitor DFO and erianin. The expression of EMT markers E-Cadherin and N-Cadherin are examined by western blotting.
- The cell death induced by the treatment with β-elemene and cetuximab in KRAS mutant CRC cells is almost completely blocked by treatment with ferroptosis rescue agents Deferoxamine (DFO; 20 nM; 24 h), Liproxstatin-1 (Lip-1) or Ferrostatin-1 (Fer-1).
- The expression of iron metabolism related protein is assessed by western blot. Protein levels of FPN1 and hepcidin1 in the liver. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloaded
- The expression of iron metabolism related protein was assessed by western blot. Protein levels of TfR1, FTH1 and FPN1 in the tibia. BL: The baseline group, mice are raised with under the GMF for 4 weeks. HLU: Mice hindlimb are unloaded and raised for 4 weeks. GMF: Mice are kept in a wooden experimental box with the normal GMF for 8 weeks. HyMF: Mice are raised in a GMF-shielded room for 8 weeks. HLU+GMF: HLU mice are reloaded and raised in a wooden box for 4 weeks. HLU+HyMF: HLU mice are reloade
- The FTL- or FTH1-knockdown A375 cells are pretreated with or without DFO (50 μM) for 2 h before CCCP stimulation. The pyroptotic morphology and LDH release are indicated.
- Quantitative analyses confirm the steady increase of blood vessels over the course of implantation of DFO-loading Gp gel.
Activité biologique
Pureté et documentation
Références
Avis client
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19. | |||||||||||||||||||||||||||||||||||||||||||||||||
In Vitro | Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis
Western Blot Analysis
Cell Proliferation Assay
Apoptosis Analysis
Western Blot Analysis
Cell Autophagy Assay
| ||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
In Vivo | Deferoxamine mesylate (6.57 μg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| ||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
656.79 | |||||||||||||||||||||||||||||||||||||||||||||||||
C26H52N6O11S | |||||||||||||||||||||||||||||||||||||||||||||||||
138-14-7 | |||||||||||||||||||||||||||||||||||||||||||||||||
Solid | |||||||||||||||||||||||||||||||||||||||||||||||||
White to off-white | |||||||||||||||||||||||||||||||||||||||||||||||||
O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O | |||||||||||||||||||||||||||||||||||||||||||||||||
Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||||||||||||||||||||||||
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) | |||||||||||||||||||||||||||||||||||||||||||||||||
In Vitro: H2O : 250 mg/mL (380.64 mM; Need ultrasonic) DMSO : 100 mg/mL (152.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing Stock Solutions
View the Complete Stock Solution Preparation Table * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo: For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
In Vivo Dissolution Calculator Please enter the basic information of animal experiments: Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments. Calculation results: Working solution concentration: mg/mL This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details. The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE). | |||||||||||||||||||||||||||||||||||||||||||||||||
|
-
[1]. Duscher D, et al. Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. Plast Reconstr Surg. 2017 Mar;139(3):695e-706e.
[2]. Dongiovanni P, et al. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol. 2008 Mar;172(3):738-47.
[3]. Wang G, et al. In vitro assessment of deferoxamine on mesenchymal stromal cells from tumor and bone marrow. Environ Toxicol Pharmacol. 2017 Jan;49:58-64.
[4]. Wu Y, et al. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct;57(3):198-205.
[5]. Bellotti D, et al. Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator. Molecules. 2021 May 28;26(11):3255.
* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
DMSO / H2O | 1 mM | 1.5226 mL | 7.6128 mL | 15.2256 mL | 38.0639 mL |
5 mM | 0.3045 mL | 1.5226 mL | 3.0451 mL | 7.6128 mL | |
10 mM | 0.1523 mL | 0.7613 mL | 1.5226 mL | 3.8064 mL | |
15 mM | 0.1015 mL | 0.5075 mL | 1.0150 mL | 2.5376 mL | |
20 mM | 0.0761 mL | 0.3806 mL | 0.7613 mL | 1.9032 mL | |
25 mM | 0.0609 mL | 0.3045 mL | 0.6090 mL | 1.5226 mL | |
30 mM | 0.0508 mL | 0.2538 mL | 0.5075 mL | 1.2688 mL | |
40 mM | 0.0381 mL | 0.1903 mL | 0.3806 mL | 0.9516 mL | |
50 mM | 0.0305 mL | 0.1523 mL | 0.3045 mL | 0.7613 mL | |
60 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.6344 mL | |
80 mM | 0.0190 mL | 0.0952 mL | 0.1903 mL | 0.4758 mL | |
100 mM | 0.0152 mL | 0.0761 mL | 0.1523 mL | 0.3806 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
- Autophagy Metabolic Enzyme/Protease NF-κB Immunology/Inflammation Apoptosis PI3K/Akt/mTOR
- Autophagy HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Apoptosis Akt
-
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Keywords:
Deferoxamine138-14-7Desferrioxamine B DFOMAutophagyHIF/HIF Prolyl-HydroxylaseReactive Oxygen SpeciesApoptosisAktHypoxia-inducible factorsHIFsHIF-PHPKBProtein kinase Bdiabetes mellitusneovascularizationcancerAlzheimer’s diseaseMEFsTAMSCsBMMSCsCOVID-19PDSH-SY5YInhibitorinhibitorinhibit
Vos produits récemment consultés:
Demande en ligne
Your information is safe with us. * Required Fields.
Bulk Inquiry
Inquiry Information
- Nom du produit:
- Deferoxamine mesylate
- Cat. No.:
- HY-B0988
- Quantité:
- MCE Japan Authorized Agent: